RAPT Therapeutics, Inc.
RAPTDelisted Mar 3, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001673772
RAPT Therapeutics, Inc. was delisted on Mar 3, 2026; its insiders filed their last Form 4 on Mar 5, 2026; 106 institutions reported holding it in 13F filings for Q4 2025, worth $1.02B in total; no superinvestor held it.
13F holders, Q4 2025
Institutional positions in RAPT Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
RAPT is no longer listed, so this page shows Q4 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 106
- +42 vs. Q3 2025
- Shares held
- 30.3M
- +13.7M (+82.7%) vs. Q3 2025
- Total value
- $1.02B
- +$593.8M (+138.7%) vs. Q3 2025
- New holders
- 50
- 36 more added
- Sold out
- 8
- 9 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RAPT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 106 | $1.02B |
| Q3 2025 | 65 | $428.0M |
| Q2 2025 | 50 | $135.6M |
| Q1 2025 | 92 | $160.0M |
| Q4 2024 | 91 | $199.5M |
| Q3 2024 | 94 | $59.9M |
| Q2 2024 | 103 | $97.0M |
| Q1 2024 | 122 | $287.2M |
| Q4 2023 | 109 | $869.3M |
| Q3 2023 | 96 | $577.8M |
| Q2 2023 | 98 | $636.7M |
| Q1 2023 | 106 | $610.5M |
| Q4 2022 | 95 | $634.7M |
| Q3 2022 | 98 | $721.0M |
| Q2 2022 | 85 | $542.7M |
| Q1 2022 | 85 | $616.1M |
| Q4 2021 | 99 | $1.02B |
| Q3 2021 | 106 | $817.8M |
| Q2 2021 | 109 | $846.6M |
| Q1 2021 | 78 | $468.4M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding RAPT Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management VI LLC | 1,562,500 | $52.9M | 16.00% | 00.0% | Unchanged |
| RTW Investments, LP | 1,637,165 | $55.5M | 0.56% | +166,666+11.3% | Added |
| OrbiMed Advisors LLC | 1,642,891 | $55.6M | 1.14% | +556,273+51.2% | Added |
| FCPM III Services B.V. | 1,833,333 | $62.1M | 8.14% | +1,489,096+432.6% | Added |
| TCG Crossover Management, LLC | 2,582,408 | $87.5M | 2.89% | +946,133+57.8% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 2,794,000 | $94.6M | 11.33% | 00.0% | Unchanged |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −91,912−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −51,406−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −50,348−100.0% | Sold out |
| Superstring Capital Management LP | 0 | $0 | 0.00% | −34,449−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | 0 | $0 | 0.00% | −9,172−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −1,080−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −154−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |